Japanese company profile · 4880
CellSource Co.,Ltd.
English company name recorded in Japan's EDINET filer data.
Original Japanese company name: セルソース株式会社
Name follows the English name recorded in EDINET filer data. English company name source
FY2024 · fiscal year ended October 2025Latest filing date: 2026-01-28What does this company do?
What does this company do?
In its FY2024 public filing, CellSource Co.,Ltd. reports Regenerative Medicine-related Business. The page shows business-level revenue and profit where the source disclosures support comparison.
CellSource Co.,Ltd.'s largest reported business by revenue in FY2024 was Regenerative Medicine-related Business.
The business with the highest reported segment profit in FY2024 was Regenerative Medicine-related Business.
FY2024 · fiscal year ended October 2025 · View original filing ↗ The source document may be in Japanese.
Reported company-wide figures
- Company revenue
- ¥3.71B ↗ FY2024 · fiscal year ended October 2025
- Operating profit
- ¥166.71M ↗ FY2024 · fiscal year ended October 2025
- Comparable margin
- 4.5% ↗ FY2024 · fiscal year ended October 2025
JGAAP · Consolidated company-wide
Company profile
Identity
- Securities code
- 4880
- EDINET code
- E35169
- Corporate number
- 3010401121829
- Listing status
- Listed
- Industry (EDINET filer classification)
- Services
Location and fiscal year
- Headquarters
- 東京都渋谷区 · As filed in Japanese
- Latest fiscal year
- FY2024
- Accounting standard
- JGAAP
- P16 data snapshot
- 2026-11-07
Company size
- Employees (consolidated)
- 148 people (FY2024)
- Employees (non-consolidated)
- 148 people (FY2024)
- Capital stock
- JPY 1.4 billion (FY2024)
Official information
- Latest annual securities report
- Latest annual securities report Opens in a new tab
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
How does it make money?
Revenue leader and profit leader
Regenerative Medicine-related Business
| Business | Sales | Share of company sales | Operating profit | Margin |
|---|---|---|---|---|
| Regenerative Medicine-related Business | ¥3.71B ↗ | — | ¥166.71M ↗ | 4.5% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2024 · fiscal year ended October 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Company-wide trend
Company revenue
JGAAP · Consolidated- FY2024
100.0 ¥3.71B
Company revenue
JGAAP · Parent-only- FY2020
64.8 ¥2.92B - FY2021
94.8 ¥4.27B - FY2022
100.0 ¥4.51B - FY2023
96.6 ¥4.36B
Company operating profit
JGAAP · Consolidated- FY2024
100.0 ¥166.71M
Company operating profit
JGAAP · Parent-only- FY2020
63.2 ¥992.44M - FY2021
100.0 ¥1.57B - FY2022
77.8 ¥1.22B - FY2023
8.2 ¥129.16M
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
What is growing?
What is growing?
No comparable reported revenue growth is available.
What has changed?
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
Company profile
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
- Growth—No comparable data
- ProfitabilityPeer-position scoreFY2024
35 - Business concentration—No comparable data
- Business change—No comparable data
- Cash generationPeer-position scoreFY2024
62 - Growth persistencePeer-position scoreFY2020→FY2021, FY2021→FY2022, FY2022→FY2023
29
Source
Public filing
FY2024 · fiscal year ended October 2025
The source document may be in Japanese.
Filing ID: S100XHWF
View original filing ↗